Detail
| LncRNA Name | TUG1 |
| Synonyms | TUG1, LINC00080, NCRNA00080, TI-227H, FLJ20618 |
| Region | GRCh38_22:30969245-30979395 Sequence |
| Ensembl | ENSG00000253352 |
| RefSeq | NR_002323 |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✘ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | pancreatic ductal adenocarcinoma |
| ICD-0-3 | C25.3 M8500/3 |
| Methods | qPCR, Western blot, Flow cytometry assay, etc. |
| Sample | The PDAC cell lines (PANC-1, PANC-28, BXPC3, SW1990). |
| Expression Pattern | up-regulated |
| Function Description | In summary, the present study revealed that TUG1 promoted the viability of PDAC cells and enhanced its resistance of gemcitabine, which might provide a theoretical basis for the development of new PDAC treatment. Surprisingly, gemcitabine combined with SCH772984 (a suppressor of ERK pathway) could reverse the drug resistance resulted from overexpression of TUG1. |
| Pubmed ID | 29960845 |
| Year | 2018 |
| Title | LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma. |
| External Links |
| Links for TUG1 | GenBank HGNC lncrnadb Noncode |
| Links for pancreatic ductal adenocarcinoma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.